About Modis Therapeutics
Modis Therapeutics is a company based in Oakland (United States) founded in 2016 was acquired by Zogenix in August 2019.. Modis Therapeutics has raised $30 million across 1 funding round from investors including Zogenix, Orbimed and F-Prime Capital. Modis Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Oakland, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Software Development Team
219 people
Leadership Team
92 people
Head Team
57 people
Global Team
39 people
Senior Team
36 people
Operations Team
36 people
Product Management Team
34 people
Human Resources and Administration
22 people
Unlock access to complete
Funding Insights of Modis Therapeutics
Modis Therapeutics has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series A round of $30 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $30.0M
-
First Round
First Round
(01 Oct 2018)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2018 | Amount | Series A - Modis Therapeutics | Valuation | F-Prime Capital , Orbimed |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Modis Therapeutics
Modis Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Zogenix, Orbimed and F-Prime Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Aceras Biomedical is focused on healthcare investment for medical innovations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Modis Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Modis Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Modis Therapeutics Comparisons
Competitors of Modis Therapeutics
Modis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Modis Therapeutics
Frequently Asked Questions about Modis Therapeutics
When was Modis Therapeutics founded?
Modis Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Modis Therapeutics located?
Modis Therapeutics is headquartered in Oakland, United States. It is registered at Oakland, California, United States.
Is Modis Therapeutics a funded company?
Modis Therapeutics is a funded company, having raised a total of $30M across 1 funding round to date. The company's 1st funding round was a Series A of $30M, raised on Oct 01, 2018.
What does Modis Therapeutics do?
Modis Therapeutics was founded in 2016 in Oakland, United States. Focus is placed on providing therapies for rare genetic diseases, particularly Thymidine kinase 2 deficiency, which causes mitochondrial dysfunction and impaired cellular energy production. Deoxynucleoside combination therapy is being developed to address mitochondrial DNA depletion disorders and restore cellular function in affected patients. Operations center on biotechnology research in the rare disease sector.
Who are the top competitors of Modis Therapeutics?
Modis Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are Modis Therapeutics's investors?
Modis Therapeutics has 5 investors. Key investors include Zogenix, Orbimed, F-Prime Capital, Aceras Biomedical, and Osage University Partners.